18th Nov 2013 07:02
Silence Therapeutics plc
Notice of Investor Event and appointment of Nominated Adviser and Broker
18 November 2013
As announced on 23 October 2013, Silence Therapeutics plc ("Silence" or the "Company") is hosting an Investor event for investors and analysts in London on Monday 18 November 2013. The purpose of the event is to explain the background to Silence's technology and outline its potential. The presentation will be available from the Company's website (silence-therapeutics.com/investor-relations) from 5pm on 18 November 2013.
In the presentation the Company will outline its plans for further drug trials, including the head and neck cancer trial announced separately today, and for targeting Angiopoietin 2 (Ang-2), a well studied vascular inflammatory agent, in the lung and systemically. The Company will also present its updated and strengthened board, senior management and scientific advisory board also announced separately today. No further material new financial or other information will be presented.
Additionally, the Company announces the appointment of Canaccord Genuity Limited as the Company's nominated adviser and broker with immediate effect.
For further information please contact:
Silence Therapeutics plc Ali Mortazavi, Chief Executive | +44 (0)333 988 0140 |
Timothy Freeborn, Finance Director | |
Annie Cheng, Chief Operating Officer
| |
|
|
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor |
|
Related Shares:
SLN.L